1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Evotec SE

Evotec SE

EVO
Evotec SEUS flagNASDAQ Global Select
2.89
USD
-0.06
- -
1.03BMarket Cap

Total Valuation

Evotec SE carries a market capitalization of 1.03B, placing it among publicly traded companies globally. Its enterprise value stands at 692.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.03B
Enterprise Value692.34M

Share Statistics

Evotec SE currently has 177.59M shares outstanding.

Shares Outstanding177.59M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.03, and the price-to-book ratio stands at -1.07.

PE RatioN/A
PS Ratio1.03
PB Ratio-1.07
P/TBV Ratio1.95
P/FCF Ratio8.51
P/OCF Ratio41.08

Enterprise Valuation

EV / Sales0.93
EV / EBITDAN/A
EV / EBITN/A
EV / FCF6.52

Financial Position

Evotec SE maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.38, indicating elevated leverage, while an interest coverage ratio of -5.64 demonstrates limited ability to service its debt obligations.

Current Ratio1.68
Quick Ratio1.49
Debt / Equity55.38
Debt / EBITDA-4.70
Interest Coverage-5.64

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-10.82
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)43.04
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover19.84

Taxes

Over the trailing twelve months, Evotec SE has paid 14.78M in income taxes, reflecting an effective tax rate of 50.37.

Income Tax14.78M
Effective Tax Rate50.37

Stock Price Statistics

Evotec SE's stock has declined approximately -28.28784% over the past 52 weeks. The 50-day moving average sits at 2.89, while the 200-day moving average is 3.29.

Beta (5Y)N/A
52-Week Price Change-28.28784%
50-Day Moving Average2.89
200-Day Moving Average3.29
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Evotec SE generated 745.04M in revenue and converted that into -193.88M in net income, yielding earnings per share of -0.55. EBITDA reached -82.42M, while operating income came in at -82.42M.

Revenue745.04M
Gross Profit85.43M
Operating Income-82.42M
Pretax Income-179.09M
Net Income-193.88M
EBITDA-82.42M
EBIT-82.42M
Earnings Per Share (EPS)-0.55

Balance Sheet

Evotec SE holds 463.78M in cash and equivalents against 387.46M in total debt, resulting in a net debt position of -89.06M. Total book value stands at -719.94M, with working capital of 287.90M providing operational flexibility.

Cash & Cash Equivalents463.78M
Total Debt387.46M
Net Debt-89.06M
Equity (Book Value)-719.94M
Book Value Per Share-2.03
Working Capital287.90M

Cash Flow

Evotec SE produced 18.71M in operating cash flow over the past twelve months. After subtracting -71.57M in capital expenditures, free cash flow totaled -52.86M - equivalent to -0.15 per share.

Operating Cash Flow18.71M
Capital Expenditures-71.57M
Free Cash Flow-52.86M
FCF Per Share-0.15

Margins

Evotec SE operates with a gross margin of 11.47, reflecting its pricing power and cost economics. The operating margin of -11.06 and net profit margin of -26.02 provide insight into operational efficiency.

Gross Margin11.47
Operating Margin-11.06
Pretax Margin-24.04
Profit Margin-26.02
EBITDA Margin-11.06

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield11.99
FCF Yield11.75

Stock Splits

Evotec SE's most recent stock split took place on October 20, 2021 with a 1:4 split ratio.

Last Split Date10/20/2021
Split Ratio1:4

Scores

Evotec SE posts an Altman Z-Score of 0.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.16